SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: Don Miller who wrote (2065)3/22/1999 10:16:00 AM
From: Don Miller  Read Replies (1) | Respond to of 10280
 
FYI, LLY dropping 3-4 points early, migraine Phase III drug test halted. Report:

Eli Lilly ends work on migraine headache drug


FRIDAY, MARCH 19, 1999 7:53 AM EST
- Reuters

PARAMUS, N.J., March 19 (Reuters) - The pharmaceutical giant Eli Lilly and Co.
(NYSE:LLY) has ended commercial development of a drug to counter migraine headache, a
Lilly collaborator said Friday.

Earlier this month the collaborator, Synaptic Pharmaceutical Corp. (NASDAQ:SNAP), said
Lilly had temporarily delayed the start of Phase III clinical trials of the migraine compound
LY334370 in order to collect additional information regarding the safety and tolerability of the
compound.

MORE

//Begin Meta Data// Selector Code: reutr Copyright 1999, Reuters News Service